29 March 2017
Time: 12:15 - 1:15pm
Venue: Michael Mason Lecture Theatre, Yvonne Carter Building, Whitechapel campus
Queen Mary Innovation, the technology transfer office of the university, aims to ensure that scientific and technological discoveries are accessible to a wider range of users who can then further develop and exploit the technology into new products, processes, applications, materials or service. In this afternoon seminar, Dr Natasa Levicar explains the process, the outputs and our interactions with the biotech/pharma/ investment sectors.
Natasa joined QMI in 2013 and focuses on the commercialisation of novel clinical and healthcare technologies and innovations arising from Barts Health NHS Trust. Prior to joining QMI, she spent almost 10 years at the interface between a biotech start-up company and academia. She was a lead scientist at a stem cell start-up company from the company’s inception. She was responsible for the development of stem cell therapeutic products for liver disease and diabetes, which resulted in the world’s first clinical trial using adult stem cells in treating damaged liver. At the same time, she held an academic appointment as a Lecturer (Assistant Professor) at Imperial College London and was a member of Board of Examiners for MSc in Surgical Sciences. She completed her PhD at King’s College London and University of Ljubljana investigating brain tumour invasion with the ultimate application for developing effective clinical therapy. In addition, she has an MSc on novel prognostic factors for high risk breast cancer patients. She is the author of several papers in scientific journals, has edited several books and is an inventor with a patent relating to healthcare innovation.